Literature DB >> 28070641

Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Kornelia E C Wirsching1, Frank Haubner2, Thomas S Kühnel2.   

Abstract

The objective of the study was to evaluate the influence of temporary nasal occlusion (tNO) with hypoallergenic tape on the frequency and severity of epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). This prospective observational study included 20 HHT patients who were undergoing Nd:YAG laser therapy at regular intervals. Over a 3-month period, laser therapy was supplemented by tNO with hypoallergenic tape for 5 h/day on average. On a 0-10 numeric rating scale, the patients reported significantly greater satisfaction in epistaxis terms after tNO treatment, with mean scores of 5 before and 7 after 3-month tNO (p = 0.05). The Epistaxis Severity Score also fell significantly from a median of 3.59-2.43 after 3-month tNO compared with laser therapy alone (p = 0.01). The patients' hemoglobin levels remained stable during the study (median: 12.2 g/dL before tNO; median: 11.7 g/dL after tNO; p = 0.387). Overall, the present study confirms the positive influence of tNO on epistaxis in HHT patients and on subjective satisfaction. This simple and inexpensive strategy is therefore a helpful option, especially in addition to regular Nd:YAG laser therapy, and is recommended by the authors.

Entities:  

Keywords:  Epistaxis; HHT; Hereditary hemorrhagic telangiectasia; Nd:YAG laser therapy; Temporary nasal occlusion; tNO

Mesh:

Year:  2017        PMID: 28070641     DOI: 10.1007/s00405-016-4431-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  33 in total

1.  Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

Authors:  Dimitri Flieger; Sabine Hainke; Wolfgang Fischbach
Journal:  Ann Hematol       Date:  2006-06-29       Impact factor: 3.673

2.  Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.

Authors:  Brigitte A Flanagan; Chris Collins; Sylvia Parra
Journal:  Cutis       Date:  2012-02

3.  A retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia.

Authors:  P A Lennox; M Harries; V J Lund; D J Howard
Journal:  J Laryngol Otol       Date:  1997-01       Impact factor: 1.469

4.  Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia.

Authors:  H C Kwaan; S Silverman
Journal:  Arch Dermatol       Date:  1973-04

5.  Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

Authors:  Sophie Dupuis-Girod; Isabelle Ginon; Jean-Christophe Saurin; Denis Marion; Elsa Guillot; Evelyne Decullier; Adeline Roux; Marie-France Carette; Brigitte Gilbert-Dussardier; Pierre-Yves Hatron; Pascal Lacombe; Bernard Lorcerie; Sophie Rivière; Romain Corre; Sophie Giraud; Sabine Bailly; Gilles Paintaud; David Ternant; Pierre-Jean Valette; Henri Plauchu; Frédéric Faure
Journal:  JAMA       Date:  2012-03-07       Impact factor: 56.272

6.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

7.  Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease.

Authors:  Benedikt J Folz; Julia Tennie; Burkard M Lippert; Jochen A Werner
Journal:  Rhinology       Date:  2005-03       Impact factor: 3.681

Review 8.  The physiological role of endoglin in the cardiovascular system.

Authors:  José M López-Novoa; Carmelo Bernabeu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-23       Impact factor: 4.733

9.  Nd:YAG laser treatment of recurrent epistaxis in heredity hemorrhagic telangiectasia.

Authors:  G A Velegrakis; E P Prokopakis; C E Papadakis; E S Helidonis
Journal:  J Otolaryngol       Date:  1997-12

10.  Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.

Authors:  Claire L Shovlin; N Laila Sulaiman; Fatima S Govani; James E Jackson; Megan E Begbie
Journal:  Thromb Haemost       Date:  2007-11       Impact factor: 5.249

View more
  2 in total

1.  [Diagnosis and treatment of Osler's disease].

Authors:  F Haubner; T Kühnel
Journal:  HNO       Date:  2018-05       Impact factor: 1.284

2.  HHT-Related Epistaxis and Pregnancy-A Retrospective Survey and Recommendations for Management from an Otorhinolaryngology Perspective.

Authors:  Kornelia E C Andorfer; Caroline T Seebauer; Carolin Dienemann; Steven C Marcrum; René Fischer; Christopher Bohr; Thomas S Kühnel
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.